

Index

A

AAM. *See* Alternatively activated macrophage
AD. *See* Alzheimer's disease
ADAM10, 224
Ahr. *See* Aryl hydrocarbon receptor
AIM2
 activation, 50, 53
 autoimmune disease, 57
 DNA sensing, 150
 lung, 52
Allergy
 components in host defense and allergy
 alternatively activated macrophage, 174
 basophil, 172
 eosinophil, 174–175
 group 2 innate lymphoid cell, 173–174
 immunoglobulin E, 171–172
 mast cell, 172
 prospects for study, 177–178
 T cells, 172–173
 group 2 innate lymphoid cell studies
 allergic airway inflammation, 159–160
 atopic dermatitis, 162
 inflammasome activation, 57
 metabolic functions of allergic module components,
 176–177
 type 2 immunity and allergy paradox, 170–171
 wound healing role of allergic module components, 177
ALS. *See* Amyotrophic lateral sclerosis
Alternatively activated macrophage (AAM). *See*
 Macrophage
ALX/FPR2, 131–132
Alzheimer's disease (AD), inflammasome activation, 55
Amyotrophic lateral sclerosis (ALS), inflammasome
 activation, 55
Angiogenesis, chronic inflammation, 191
AP-1, inflammatory response, 37–40, 88
Apoptosis, DNases
 caspase-activated DNase, 141–143
 DNase II, 144–145
APRIL, 208
Areg, 157
Arid5A, 90–92
Arnt, 89
Arteriole. *See* Microvascular system
Aryl hydrocarbon receptor (Ahr), 89–90
ASC, 45, 49–50
Aspirin-triggered lipotoxins (ATL), inflammation
 resolution, 125–126

Atherosclerosis, inflammasome activation,
 54–55
ATL. *See* Aspirin-triggered lipotoxins
Atopic dermatitis. *See* Allergy
Autophagy, Toll-like receptor linking, 26–27

B

BAI1, 144
Basophil
 allergy and immune response role, 172
 chemokine system in homeostasis, 107
B cell, innate B cells and sentinel pathogen permissive
 cells, 71–72
Blood vessels. *See* Microvascular system
BLT1, 131
BSF-2, 85
BTLA
 defects and disease, 76–78
 dendritic cell regulation, 76
 $\gamma\delta$ T cell regulation, 74–76
 innate immunity role, 68, 72–73
 natural killer cell antiviral activation, 73–74

C

CAD. *See* Caspase-activated DNase
Capillary. *See* Microvascular system
CAPS. *See* Cryoprin-associated periodic syndromes
Caspase-activated DNase (CAD)
 apoptosis, 141–143
 defects
 autoinflammation activation, 145–146
 cancer and autoimmune disease, 143–144
 inhibitor complex, 142
 pyrenocyte DNA digestion, 145
Cathepsins, Toll-like receptor cleavage, 23
CCL21, 71
CCR7, dendritic cell function, 36
CD14, Toll-like receptor signaling, 6, 22–23
CD25, 176
CD99, 188
CD160
 defects and disease, 76–78
 innate immunity role, 72–73
 natural killer cell antiviral activation, 73–74
CD169, macrophage expression at lymphohematopoietic
 interface, 203
cGAS. *See* Cyclic GMP-AMP synthase

Index

- Chemokines. *See also specific chemokines and receptors*
acute inflammation role
induction by resident immune cells, 109–110
overview, 108–109
recruitment of cells
dendritic cell, 113
eosinophil, 113
innate lymphoid cell, 114
monocyte, 112–113
neutrophil, 110–112
evolution, 103, 105
innate immune cell homeostasis role
basophil, 107
dendritic cell, 107–108
developing cells, 105
eosinophil, 107
innate lymphoid cell, 108
mast cell, 107
monocyte, 105–107
neutrophil, 105
leukocyte recruitment, 186–187
prospects for study, 115
receptor expression and function, 103–104
T-cell priming
CD8 cell, 115
Tfh cell, 114–115
Th1 cell, 114
Th2 cell, 114–115
types and receptors, 101–103
ChemR23, 131
Chronic rhinosinusitis (CRS), group 2 innate lymphoid
cell studies, 161–162
cis-regulatory elements, identification in inflammatory
gene expression, 40
CLRs. *See* C-type lectin receptors
CpG island, nucleosome positioning, 39–40
C-reactive protein (CRP), 86, 93
CRP. *See* C-reactive protein
CRS. *See* Chronic rhinosinusitis
Cryoprin-associated periodic syndromes (CAPS), inflam-
masome activation, 54
CS36, Toll-like receptor signaling, 6
C-type lectin receptors (CLRs), 20–21
CXCL13, 69, 71
Cyclic GMP-AMP synthase (cGAS), intracellular DNA
sensing, 11–12, 27–29, 150
- D**
DAI, intracellular DNA sensing, 11, 150
DC. *See* Dendritic cell
DC-SIGN (SIGNR1), macrophage expression at
lymphohematopoietic interface, 204–206
DDX41, intracellular DNA sensing, 11
Death receptors, 142
Dectins, 21
Dendritic cell (DC)
antigen targeting to marginal zone, 207
aryl hydrocarbon receptor, 90
chemokine system
homeostasis, 107–108
recruitment in acute inflammation, 113
follicular, 200
inflammatory gene expression program, 36–37
TNFSF regulation, 76
DHA. *See* Docosahexaenoic acid
DHX9, intracellular DNA sensing, 11
DHX36, intracellular DNA sensing, 11
Diabetes, inflammasome activation in type 2
disease, 55
DLAD, 146
DNA-PK, intracellular DNA sensing, 11
DNases
caspase-activated DNase
apoptosis, 141–143
defects in cancer and autoimmune disease,
143–144
inhibitor complex, 142
cytosolic DNA sensing, 150
DNase II
apoptotic cell DNA digestion, 144–145
defects in autoinflammation activation, 145–146
pyrenocyte DNA digestion, 145
DNase II-like acid DNase, 146
prospects for study, 150–151
signal transduction, 148–150
Trex1, 146–148
Docosahexaenoic acid (DHA), inflammation
resolution, 124
- E**
Eicosapentaenoic acid (EPA), inflammation
resolution, 124
Endothelial cell
capillary leak, 191
homeostatic function, 185
microvascular system, 184
postcapillary venules, plasma protein extravasation,
and leukocyte recruitment, 186–189
thrombosis, 190
Enhancers, inflammatory gene expression, 40–42
Eosinophil
allergy and immune response role, 174–175
chemokine system
homeostasis, 107
recruitment in acute inflammation, 113
metabolic homeostasis role, 176
Eosinophilic pleural effusion (EPE), group 2 innate
lymphoid cell studies, 161
EPA. *See* Eicosapentaenoic acid
EPE. *See* Eosinophilic pleural effusion
- F**
F4/80, macrophage expression at lymphohematopoietic
interface, 202–203
FACS. *See* Familial cold autoinflammatory syndrome

Familial cold autoinflammatory syndrome (FACS), inflammasome activation, 54

FoxA, inflammatory response, 38

FOXP3, 173

FPR1, 110, 112

G

$\gamma\delta$ T cell, BTLA regulation, 74–76

GATA3, 157, 173

Gout, inflammasome activation, 54

gp96, 22

gp130, 92

GPR32, 131–132

H

HAT. *See* Histone acetyltransferase

Hepatocyte-stimulating factor (HSF), 85

Herpes virus entry mediator (HVEM)

defects and disease, 76–78

innate immunity role, 68, 72–75

HGF. *See* Hybridoma growth factor

Histone acetyltransferase (HAT), inflammatory gene expression regulation, 40–42

HMGB1, 87, 150, 221

HSE. *See* Hepatocyte-stimulating factor

HVEM. *See* Herpes virus entry mediator

Hybridoma growth factor (HGF), 85

I

ICAM-1. *See* Intercellular adhesion molecule-1

IFI16, 50

IFIX, 50

IgE. *See* Immunoglobulin E

IL-1. *See* Interleukin-1

IL-6. *See* Interleukin-6

ILC. *See* Innate lymphoid cell

Immunoglobulin E (IgE), allergy and immune response role, 170–172

Inflammasome

activation

AIM2, 50

allergens and particulates, 57

Alzheimer's disease, 55

amyotrophic lateral sclerosis, 55

atherosclerosis, 54–55

autoimmune disease, 56–57

cryoprin-associated periodic syndromes, 54

diabetes, 56

gout, 54

metabolic syndrome, 56

NLRC4, 49–50

NLRP1, 47

NLRP3, 47–49

NLRP6, 49

NLRP12, 49

RIG-I, 50

CARD domains, 46–47

commensal microbiota response, 53

functional overview, 43–45

host defense against infection

intestine, 51–52

lung, 52–53

overview, 50–51

prospects for study, 57–58

Inflammation resolution

anti-inflammation versus proresolution processes, 124

docosahexaenoic acid, 124

eicosapentaenoic acid, 124

G-protein-coupled receptors, 131–132

infection relationship, 130–131

microRNA roles, 132

specialized proresolving mediators

animal disease model studies, 132–134

human disease studies, 125, 127

identification, 122–124

maresins, 128–130

metabololipidomics profiling, 130

overview, 121–122

structure elucidation, 124–126, 128

Influenza, group 2 innate lymphoid cell studies, 159

Innate lymphoid cell (ILC)

chemokine system

homeostasis, 108

recruitment in acute inflammation, 114

group 2 cells

adipose tissue function, 163–164

allergy and immune response role, 173–174

atopic dermatitis studies, 162

effector functions, 157–158

functional overview, 157

gut function, 158–159

identification, 157

liver function, 162–163

prospects for study, 164–165

regulation, 157–158

respiratory tract function

allergic airway inflammation, 159–160

chronic rhinosinusitis, 161–162

eosinophilic pleural effusion, 161

influenza, 159

pulmonary fibrosis, 161

lymphotoxin- $\alpha\beta$ and TNFR-dependent immunity, 69–71

markers, 155–156

subsets, 156–157

Intercellular adhesion molecule-1 (ICAM-1), leukocyte recruitment, 187–189

Interferon regulatory factors (IRFs)

inflammatory response, 37–39

IRF7, 206

Interferon- α , innate B cells and sentinel pathogen

permissive cells, 71–72

Index

- Interferon- β
innate B cells and sentinel pathogen permissive cells, 71–72
macrophage expression, 141
- Interleukin-1 (IL-1)
atherosclerosis studies, 55
reflex regulation of innate immunity, 222–223
- Interleukin-6 (IL-6)
functional overview, 85–87
prospects for study, 95–96
receptor
expression and function, 89–90
signaling, 92–93
synthesis regulation, 87–89
therapeutic targeting, 93–94
transcript stabilization and regulation, 90–92
- IPEX, 173
- IRAKs, Toll-like receptor signaling, 6–7
- IRFs. *See* Interferon regulatory factors
- J**
- JAK, interleukin-6 signaling, 92–93
- K**
- KLF-4, 189
- L**
- LBP. *See* Lipopolysaccharide-binding protein
- LC3, 26–27, 29
- Leukotriene B₄ (LTB₄), neutrophil production, 110–112
- LFA-1, 187
- LGP2, intracellular virus recognition, 8–10
- LIGHT (TNSF-14)
defects and disease, 76–78
innate immunity role, 67–68, 72–73
- Lipopolysaccharide-binding protein (LBP), 23
- Lipoxin A₄ (LXA₄)
group 2 innate lymphoid cell studies, 158, 160
inflammation resolution, 123, 125–126, 131, 134
- LTB₄. *See* Leukotriene B₄
- LTi. *See* Lymphoid tissue inducer
- LXA₄. *See* Lipoxin A₄
- Lymph node subcapsular sinus (SCS), macrophages
functions, 205–209
lipid regulation, 208–209
overview, 195–197, 201
phenotypic characterization
DC-SIGN, 204
F4/80, 202–203
CD169, 203
mannose receptor, 203–204
MARCO, 204–205
prospects for study, 209–212
species differences, 209
- Lymphoid tissue inducer (LTi), 108
- Lymphotoxin- α , 68, 70
- Lymphotoxin- β , 69–71
- Lymphotoxin- β receptor, 68, 70–71, 76
- M**
- Macrophage
alternatively activated macrophage, allergy and immune response role, 174
apoptotic cell engulfment, 144
inflammation resolution, 128–130
lymphohematopoietic interface. *See* Lymph node subcapsular sinus; Medullary sinus macrophage; Spleen marginal zone
- Mannose-binding lectin (MBL), 24
- Mannose receptor, macrophage expression at lymphohematopoietic interface, 203–204
- MARCO, macrophage expression at lymphohematopoietic interface, 204–205
- Maresins, inflammation resolution, 125, 128–130
- Marginal zone. *See* Spleen marginal zone
- Mast cell
allergy and immune response role, 172
chemokine system in homeostasis, 107
- MAVS, 28
- MBL. *See* Mannose-binding lectin
- MD2, Toll-like receptor signaling, 22–23
- MDA5
intracellular virus recognition, 8–10
RNA binding, 27–28
- MDP. *See* Muramyl dipeptide
- Medullary sinus macrophage (MSM), functions, 207–208, 211
- Metabolic syndrome, inflammasome activation, 56
- MicroRNA (miRNA)
inflammation resolution, 132
interleukin-6 expression regulation, 89
Toll-like receptor signaling modulation, 8
- Microvascular system
angiogenesis in chronic inflammation, 191
arterioles and control of blood flow, 185–186
capillary leak, 190–191
flow dysregulation, 190
homeostatic function, 185
organization, 183–185
postcapillary venules, plasma protein extravasation, and leukocyte recruitment, 186–190
thrombosis, 190
- MIF, 112
- miRNA. *See* MicroRNA
- MNDA, 50
- Monocyte, chemokine system
homeostasis, 105–107
recruitment in acute inflammation, 112–113
- Mre11, 150
- MSM. *See* Medullary sinus macrophage
- Muckle–Wells syndrome, inflammasome activation, 54
- Muramyl dipeptide (MDP), 47
- MyD88, Toll-like receptor signaling, 6, 24–25, 149
- MZ. *See* Spleen marginal zone

- N**
- nAChR. *See* Nicotinic acetylcholine receptor
- Neutrophil, chemokine system
homeostasis, 105
recruitment in acute inflammation, 110–112
- NF- κ B. *See* Nuclear factor- κ B
- Nicotinic acetylcholine receptor (nAChR), reflex regulation
of innate immunity, 221
- NLRC4
activation, 49–50
intestine, 51
lung, 52
- NLRP1
activation, 47
autoimmune disease, 56
lung, 52
- NLRP3
activation, 47–49, 53
atherosclerosis studies, 55
autoimmune disease, 56–57
commensal microbiota response, 53
cryoprin-associated periodic syndrome role, 54
gout response, 54
insulin resistance, 56
intestine, 51
lung, 52
neurodegenerative disease, 55
particulate activation, 57
viral RNA activation, 10
- NLRP6
activation, 49
commensal microbiota response, 53
- NLRP12, activation, 49
- Nrdp-1, Toll-like receptor signaling, 6
- Nuclear factor- κ B (NF- κ B)
interleukin-6 transcription regulation, 89
nucleosome/transcription factor interplay in
inflammatory response, 39
Toll-like receptor signaling, 6
- Nucleosome
CpG islands in positioning, 39–40
evolution, 216
regulatory elements controlling inflammatory gene
expression
cis-regulatory elements, 40
enhancers, 40–42
transcription factor interplay in inflammatory response,
38–39
- O**
- Oxidative stress, NLRP3 activation, 48
- P**
- p53, 89
p300, 40
- Pattern recognition receptors. *See specific receptors*
- PC. *See* Pericyte
- PECAM-1, 188
- Pericyte (PC)
chemokines, 189
microvascular system, 184–185
- PMN. *See* Polymorphonuclear neutrophil
- Pol II. *See* RNA polymerase II
- Polo-like kinases, Toll-like receptor signaling, 8
- Polymorphonuclear neutrophil (PMN), inflammation
induction and resolution, 122–123
- PRAT4A, 22
- Protectin, inflammation resolution, 125
- Pu.1, inflammatory response, 40, 42
- Pulmonary fibrosis, 161
- Pyrenocyte, DNA digestion, 145
- R**
- RA. *See* Rheumatoid arthritis
- Rab5, 144
- RAGE, 87
- Regnase-1, 90–92
- Resolvins, inflammation resolution, 125–134
- Rheumatoid arthritis (RA), interleukin-6 role
and targeting, 93–95
- Rhinosinusitis. *See* Chronic rhinosinusitis
- RIG-I
activation, 50
intracellular virus recognition, 8–10
lung, 52
RNA binding, 27–28
- RNA polymerase II (Pol II), inflammatory gene expression
regulation, 39–40
- RNF135, RIG-I-like receptor signaling modulation, 10
- S**
- S100, 87
- SAA. *See* Serum amyloid A
- SCS. *See* Lymph node subcapsular sinus
- Sec5, 29
- Serum amyloid A (SAA), 86
- SHP-1, 75
- SHP-2, 73, 75
- SIGNR1. *See* DC-SIGN
- SLE. *See* Systemic lupus erythematosus
- SMC. *See* Smooth muscle cell
- Smooth muscle cell (SMC), microvascular system,
183–185
- SOCS, 93
- SP1, 39, 88
- Specialized proresolving mediators (SPM). *See*
Inflammation resolution
- Sphingosine-1-phosphate receptor, 108
- Spleen marginal zone (MZ)
anatomy, 197–200, 202
antigen targeting, 207
macrophages
functions, 205–207
overview, 195–197, 201

Index

- Spleen marginal zone (MZ) (*Continued*)
 phenotypic characterization
 CD169, 203
 DC-SIGN, 204
 F4/80, 202–203
 mannose receptor, 203–204
 MARCO, 204–205
 prospects for study, 209–212
 species differences, 209
- SPM. *See* Specialized proresolving mediators
- Stabilin2, 144
- STATs
 aryl hydrocarbon receptor interactions, 89–90
 inflammatory response, 37–39
 interleukin-6 signaling, 92–93
- STING, intracellular DNA sensing, 11–13, 29, 149–150
- Subcapsular sinus. *See* Lymph node subcapsular sinus
- Systemic lupus erythematosus (SLE), 144
- T**
- TAT, 89
- TBK1, intracellular DNA sensing, 11, 13, 29
- T cell. *See also* $\gamma\delta$ T cell
 allergy and immune response role, 172–173
 chemokines in priming
 CD8 cell, 115
 Tfh cell, 114–115
 Th1 cell, 114
 Th2 cell, 114–115
- Thymic stromal lymphopoietin (TSLP), 157–160
- Tim4, 144, 206
- TIRAP, Toll-like receptor signaling, 25–26
- TLRs. *See* Toll-like receptors
- TNF. *See* Tumor necrosis factor
- TNFR1, 67–68
- TNFR2, 67–68
- TNSF-14. *See* LIGHT
- Tocilizumab, 93–94
- Toll-like receptors (TLRs)
 cleavage, 23
 evolution, 216
 expression, structure, and ligands
 cell surface receptors, 3–4, 22–23
 endosomal receptors, 4–6
 intracellular DNA sensing, 10–11
 overview, 1–3, 20–22
 phagocytosis and autophagy linkage, 26–27
 signaling
 overview, 6–8
 sorting adaptor proteins, 25–26
 subcellular localization dependence, 24–25
 subcellular distribution, 22–24
 TRAF, Toll-like receptor signaling, 6–7
 TRAIL, 142
 TRAM, Toll-like receptor signaling, 25–26
 Trem14, 206
 Trex1, 146–148
 TRIF, Toll-like receptor signaling, 6, 24, 149
 TRIM25, RIG-I-like receptor signaling
 modulation, 10
- TSLP. *See* Thymic stromal lymphopoietin
- Tumor necrosis factor (TNF)
 angiogenesis in chronic inflammation, 191
 reflex regulation of innate immunity, 219–221
- U**
- UL144, 74
- UNC93b1, 22–23
- Unilateral ureteric obstruction (UUO), 134
- UUO. *See* Unilateral ureteric obstruction
- V**
- Vagus nerve, reflex regulation of innate immunity, 219–223
- Vascular cell adhesion molecule-1 (VCAM-1), leukocyte
 recruitment, 187–189
- Vascular endothelial growth factor (VEGF), 87, 191
- Vasculature. *See* Microvascular system
- VCAM-1. *See* Vascular cell adhesion molecule-1
- VEGF. *See* Vascular endothelial growth factor
- VLA-4, 187–188
- W**
- WHIM syndrome, 105
- Wound healing, role of allergic module components, 177
- X**
- Xkr8, 144
- Z**
- ZIP14, 86